Physician profile
Kevin Kasper
NPI 1699749036
$1,402.35
in general payments reported to CMS, 2019-2025
18 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $19.09 · 2021: $16.20 · 2022: $424 · 2023: $34.20 · 2024: $208 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $232.80 | 2024-2025 | Wegovy |
| Impulse Dynamics (USA) INC. | $190.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $160.18 | 2019-2025 | |
| Cleerly, INC. | $127.07 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Endotronix, INC. | $126.57 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.34 | 2024-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $90.66 | 2022 | |
| Kestra Medical Technology Services, INC. | $74.28 | 2025 | Assure Wcd |
| Amgen INC. | $49.82 | 2024-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $39.77 | 2025 | Onpattro |
| E.R. Squibb & Sons, L.L.C. | $38.95 | 2024 | Eliquis |
| Abiomed | $34.20 | 2023 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $26.75 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $19.84 | 2025 | Nexletol |
| Resmed Corp | $19.09 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $17.29 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.57 | 2024 | Farxiga |
| Abbott Laboratories | $13.96 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Kasper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.